Clinical trial
Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular…
NCT00280007 · Medical University of Vienna, Other · Terminated
Key facts
| NCT number | NCT00280007 |
|---|---|
| Title | Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma |
| Official title | AVATACE-1: Bevacizumab (Avastin®) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | bevacizumab |
| Enrollment | 32 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2010 |
| First posted | Jan 20, 2006 |
| Last update posted | Apr 22, 2010 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: